Intended for healthcare professionals

Editorials

Suspend intellectual property rights for covid-19 vaccines

BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1344 (Published 28 May 2021) Cite this as: BMJ 2021;373:n1344

Read our latest coverage of the coronavirus pandemic

  1. Priti Krishtel, co-executive director1,
  2. Rohit Malpani, global health consultant
  1. 1Initiative for Medicines, Access, and Knowledge (I-MAK), Oakland, CA, USA
  2. 2Paris, France
  1. Correspondence to: P Krishtel priti{at}i-mak.org
    @pritikrishtel on Twitter

Waivers are essential for global vaccine equity

The United States caught the world by surprise on 5 May 2021 when it announced its intention to support a World Trade Organization proposal that would temporarily waive intellectual property rights on covid-19 vaccines. While this move is encouraging, the Biden administration’s support is the first step of many required.1

Waiving intellectual property rights is essential to tackle serious inequity in the global distribution of covid-19 vaccines, whereby wealthy countries currently control the lion’s share of existing supplies. By the end of April, over 1.3 billion doses had been administered worldwide, but only 0.2% of vaccines had been given in low income countries.2

More than one year into the pandemic, the situation is at a low point globally. The average number of weekly deaths in April was over 36 000 in just India and Brazil,3 and variants are proliferating. Experts fear a devastating second wave across Asia and Africa.4

Voluntary action has not worked— whether timely sharing of doses with low and middle income countries or sharing knowledge through the World Health Organization. It’s time for mandatory rules and legal commitments that can help put an end to this pandemic.

The proposed intellectual property waiver is appropriate as vaccine manufacturers have relied heavily on publicly funded research into coronaviruses.5 Together, companies holding intellectual property rights are estimated to have benefited from government funding of around €93bn (£80bn; $110bn).6 The Moderna vaccine was funded almost exclusively by the US government.7

A successfully negotiated intellectual property waiver would ensure manufacturers cannot block production or access to raw materials and finished products for covid-19 technologies worldwide. A waiver would also prevent companies from charging unaffordable prices while insulated from competition.

Lack of competition in the vaccines market has a long history. Previously, the two companies with a duopoly for the human papillomavirus (HPV) vaccine8 held patents that prevented competition. According to one estimate, low income countries paid up to 10 times the estimated cost of production for these vaccines.9 Millions of girls globally are still unable to access this critical protection against cervical cancer.

Similarly, Pfizer successfully enforced secondary patents on its pneumococcal vaccine through legal proceedings in India10 and South Korea,11 which delayed competition. Pneumonia remains the leading cause of death globally among children under 5 years old.12 Many middle income countries have low coverage because of the high price of the vaccine, often 5-10 times higher than the lowest price available globally.13

Inadequate access to essential vaccines is predictable in a system that prioritises monopolies—and this will repeat itself in the absence of an intellectual property waiver for covid-19 vaccines.

Key features

A successfully negotiated waiver would meet four important criteria. The waiver’s primary aim should be to save as many lives as possible. The Biden administration wants the waiver to focus on vaccines. This constraint should be removed. The original proposal applies to all medical technologies related to covid-19, including diagnostics, medicines, and ventilators. Many people are likely to become sick even if vaccination rates improve worldwide.

Secondly, negotiations should be completed quickly. Governments should make substantial progress ahead of the WTO meeting on 8 June 2021. Thirdly, any waiver should be straightforward, unambiguous, for a reasonable duration, and limit manufacturers’ ability to file legal challenges that impede access.

Finally, negotiating texts should be fully disclosed, with negotiations transparent to ensure all countries negotiate as equals. In the past, powerful nations have used their leverage to extract concessions from less powerful countries behind closed doors.14

Opponents of a waiver question whether manufacturers in lower income countries have the required capabilities. This argument was also made in the 1980s when Merck and GSK dominated the market for complex recombinant hepatitis B vaccines. It was discredited in 1997, when Indian manufacturer Shantha Biotechnics launched a vaccine that reduced the cost of a dose from up to $23 to just $1. Many millions of people worldwide have since been successfully immunised.15 Manufacturers in low and middle income countries are already critical to overall immunisation efforts worldwide: in 2018, they provided over half of the 2.4 billion vaccine doses procured by Unicef.16

Suppliers worldwide are gearing up to meet this moment. New mRNA vaccines are under development in India17 and China,18 and several companies in middle income countries are already manufacturing covid-19 vaccines.1920 WHO is establishing a technology transfer hub to support local production of mRNA vaccines.21 Although follow-on manufacturers can produce complex vaccines without support from holders of technology, sharing knowledge would save time and lives.

As we enter into a new era of global pandemics, we must fundamentally rethink the global intellectual property system. The ability to respond swiftly to global crises cannot be left to a handful of private companies in a few wealthy countries. We need a more cooperative global response to this and future public health emergencies.

Footnotes

  • Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: RM is a board member of Unitaid.

  • Provenance and peer review: Commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

References

View Abstract